MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, April 4, 2013

Biogen Idec takes full ownership of Tysabri

3 April 2013 10:51 in Pharmaceutical Company Product News 

Biogen Idec has announced the completion of its move to acquire full strategic, commercial and decision-making rights to the multiple sclerosis (MS) drug Tysabri.

The company has bought out its partner Elan's share in the therapy in order to further strengthen its leadership in the MS treatment field and take a more active role in maintaining the future growth trajectory of the product.

Tysabri is approved in more than 65 countries, including a European indication for highly active relapsing-remitting MS in adult patients who have failed to respond to beta interferon or have rapidly evolving severe RRMS.

Biogen Idec is also currently carrying out a clinical study assessing the potential benefits the compound can offer in the treatment of secondary progressive MS.

In exchange for the full rights to the drug, Biogen Idec has paid Elan an upfront fee of $3.25 billion (2.15 billion pounds) plus tiered contingent payments based on future Tysabri worldwide sales.

Dr George Scangos, chief executive officer of Biogen Idec, said: "We are grateful to Elan for more than a decade of collaboration on Tysabri and for their work to provide a seamless transition as we finalised the transaction."ADNFCR-8000103-ID-801565663-ADNFCR



USE OUR SHARE LINKS at the top of this page  - to provide this article to others

If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left

REMAIN up to date with MS News and Education
Visit:  to register


No comments: